Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
Date:2/5/2009

ATLANTA, Feb. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that 2008 fourth quarter and year end financial results will be released on Thursday, February 19, 2009. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 19, 2009, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available February 19 through February 26 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 312509.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France and Canada for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:

http://www.cryolife.com.

    D. Ashley Lee                                   Katie Brazel
    Executive Vice President,                       Fleishman Hillard
    Chief Financial Officer and                     Phone: 404-739-0150
    Chief Operating Officer
    Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
2. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
3. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
4. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
5. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
6. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
7. CryoLife to Present at UBS Global Life Sciences Conference
8. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
9. CryoLife Announces Management Promotions
10. CryoLifes Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007
11. CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 19, 2017 , ... As part ... webinars accessible to novices as well as experienced users, attendees will gain a ... coagulation screening tests. , Hemostasis testing quality is determined by preanalytical variables ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, 2017 /PRNewswire/ ... finance firm that provides senior debt to life ... closing of a $20 million senior secured term ... company engaged in the development and commercialization of ... orthopedic injuries. Cerapedics, lead product, i-FACTOR ...
(Date:4/18/2017)... Urdorf, Switzerland (PRWEB) , ... April 18, 2017 ... ... a smartphone/tablet app that converts conductivity readings to concentration levels and vice-versa. , ... analytical chemistry is analyzing solution strength in concentration control or monitoring. The principle ...
(Date:4/18/2017)... ... April 18, 2017 , ... Whitehouse Laboratories is ... MD&M East has helped take medical devices from concept to market by ... minds. , Whitehouse labs will showcase its diverse and comprehensive capabilities which are ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):